E(1F&k2G(1F&l1H&n11WdLetterhead&l7C&a200CType=%(Type)s;npat=%(npat)s;nSS=%(nSS)s   ;nmob=%(nmob)s    ;tel=                  ;cmed=%(cmed)s;suf=          ;
&a200Cpfx=%(pfx)s ;pnom=%(pnom)s              ;prn=%(prn)s            ;ad1=%(ad1)s                         ;datedos=%(datedos)s;
&a200Cad2=%(ad2)s                         ;ad3=                                        ;numdos=%(numdos)s ;ddn=%(ddn)s;
&a200Cnommed=%(nommed)s        ;ccor=        ;nomcor=                                        ;age=%(age)s  ;
&a200Ctdu=       ;cprl=%(cprl)s     ;nprl=%(nprl)s               ;tprl=                ;
&a-5R(s0p10h12v0s0b3T(1F                                            %(numdos)s (s0p16h8.v0s0b3T(1F -%(datedos)s-          -p1/2  (s0p10h12v0s0b3T(1F 





&a12R                                  
                                          %(pfx)s  %(pnom)s %(prn)s          
                                          NJF:SHELLI              
                                          %(ad1)s                         
  %(nommed)s        %(ad2)s                         
  Hopital Tenon                           
  4 rue de la Chine                       
  75020 PARIS                                    Besan\on, le%(datedos)s @13H31
  Dossier N[%(numdos)s du(s0p10h12v0s3b3T(1F %(datedos)s                                         (s0p10h12v0s0b3T(1F 


    (s1p16v0s4101T(1F                        SEROLOGIE DES HEPATITES VIRALES            (s0p10h12v0s0b3T(1F

   (s0p10h12v0s3b3T(1FHEPATITE B                                                                  (s0p10h12v0s0b3T(1F

   Anticorps anti-HBs . . . . . . . . . . .          1  UI/l
    (s0p16h8.v0s0b3T(1F(*) Technique E.I.A. avec r{actif ABBOTT sur Architect (s0p10h12v0s0b3T(1F

   (s0p16h8.v0s0b3T(1FINTERPRETATION                                                                                   (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  Absence d'immunit{ : inf{rieur @ 5                                                    (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  Immunit{ post infectieuse : sup{rieur @ 10                                            (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  Immunit{ post vaccinale(3 injections) : 100                                           (s0p10h12v0s0b3T(1F

   Anticorps anti-HBc(IgM+IgG). . . . . . .    N{gatif
    (s0p16h8.v0s0b3T(1F(*) Technique E.I.A. avec r{actif ABBOTT sur Architect (s0p10h12v0s0b3T(1F
    (s0p16h8.v0s0b3T(1F                                                   Index: (s0p10h12v0s0b3T(1F         (s0p16h8.v0s0b3T(1F   0.13 (s0p10h12v0s0b3T(1F  (s0p16h8.v0s0b3T(1F   inf. @ 1.00    (s0p10h12v0s0b3T(1F



    (s1p16v0s4101T(1F                                      I M M U N O L O G I E        (s0p10h12v0s0b3T(1F

   (s0p10h12v0s3b3T(1FSERODIAGNOSTIC DE LA TOXOPLASMOSE                                           (s0p10h12v0s0b3T(1F

   Deuxi}me d{termination

     IgG antitoxoplasmique. . . . . . . . .          0 UI/ml
     IgM antitoxoplasmique. . . . . . . . .    N{gative

     SERUM PRECEDENT DU 21/03/14

     IgG antitoxoplasmique. . . . . . . . .          0 UI/ml
     IgM antitoxoplasmique. . . . . . . . .    N{gative

   (s0p16h8.v0s0b3T(1FINTERPRETATION                                                                                   (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  Immunite absente ou insuffisante: Ig G inf. @ 2 UI/ml                                 (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  Immunite {quivoque: IgG : 2 @ 3 UI/ml                                                 (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  Immunit{ acquise : IgG sup.ou {gal @ 3 UI/ml                                          (s0p10h12v0s0b3T(1F
   (s0p16h8.v0s0b3T(1F  IgM n{gative: index inf. @ 0,5                                                        (s0p10h12v0s0b3T(1F







(s0p16h8.v0s0b3T(1F (s0p10h12v0s0b3T(1F     
                                               &a69R&a58C(s0p16h8.v0s0b3T(1F r{sultats RECTOVERSO(s0p10h12v0s0b3T(1F 
&a71R&a10C(s0p16h8.v0s0b3T(1F (s0p10h12v0s0b3T(1F &a71R&a33.5C(s0p16h8.v0s0b3T(1F Biologiste M{dical(s0p10h12v0s0b3T(1F &a71R&a61C(s0p16h8.v0s0b3T(1F J.ALMARCHA(s0p10h12v0s0b3T(1F 
(s0p16h8.v0s0b3T(1F Dossier n[ %(numdos)s  du %(datedos)s %(pfx)s  %(pnom)s %(prn)s                     n{(e) le :: 23/02/78(s0p10h12v0s0b3T(1F 


    (s1p16v0s4101T(1F                         CHIMIE DES URINES  (sur {chantillon)      (s0p10h12v0s0b3T(1F

   GLYCOSURIE . . . . . . . . . .    Absence

   PROTEINURIE . . . . . . . . .     Absence
    (s0p16h8.v0s0b3T(1FBandelettes Combur-Test Roche-Dosage sur plaque Vitros UPRO-OrthoClinicalDiagnostic (s0p10h12v0s0b3T(1F




















(s0p16h8.v0s0b3T(1F (s0p10h12v0s0b3T(1F     
                                           &a69R&a58C(s0p16h8.v0s0b3T(1F r{sultats RECTOVERSO(s0p10h12v0s0b3T(1F 
&a71R&a10C(s0p16h8.v0s0b3T(1F (s0p10h12v0s0b3T(1F &a71R&a33.5C(s0p16h8.v0s0b3T(1F Biologiste M{dical(s0p10h12v0s0b3T(1F &a71R&a61C(s0p16h8.v0s0b3T(1F J.ALMARCHA(s0p10h12v0s0b3T(1F               &a200Cff##